tradingkey.logo
tradingkey.logo
Search

Edwards Lifesciences Corp

EW
Add to Watchlist
86.374USD
+0.494+0.57%
Market hours ETQuotes delayed by 15 min
49.84BMarket Cap
45.87P/E TTM

TradingKey Stock Score of Edwards Lifesciences Corp

Currency: USD Updated: 2026-06-22

Key Insights

Edwards Lifesciences Corp's fundamentals are relatively very healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 17 out of 203 in the Healthcare Equipment & Supplies industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 96.03.In the medium term, the stock price is expected to remain stable.Despite an average stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Edwards Lifesciences Corp's Score

Industry at a Glance

Industry Ranking
17 / 203
Overall Ranking
92 / 4577
Industry
Healthcare Equipment & Supplies

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score
Previous score

Media Coverage

Last 24 hours
Coverage Level

19°C

Very Low
Very High
Positive

Edwards Lifesciences Corp Highlights

StrengthsRisks
Edwards Lifesciences Corporation is the global structural heart company. The Company partners with clinicians and researchers and invests in research and development to improve care for those impacted by structural heart disease. Its product categories include Transcatheter Aortic Valve Replacement (TAVR), Transcatheter Mitral and Tricuspid Therapies (TMTT), and Surgical Structural Heart. It provides transcatheter heart valve replacement technologies designed for the minimally-invasive replacement of aortic heart valves. TAVR category includes the Edwards SAPIEN 3, the Edwards SAPIEN 3 Ultra and the Edwards SAPIEN 3 Ultra RESILIA systems. TMTT category includes the PASCAL Precision transcatheter repair system, EVOQUE tricuspid valve replacement system and Cardioband tricuspid valve reconstruction system. Its INSPIRIS RESILIA aortic valve, offers RESILIA tissue and VFit technology. It is managed in various geographical regions, such as United States, Europe, Japan and Rest of World.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 21.11% year-on-year.
Overvalued
The company’s latest PE is 45.61, at a high 3-year percentile range.
Institutional Selling
The latest institutional holdings are 539.60M shares, decreasing 2.34% quarter-over-quarter.
Held by Andreas Halvorsen
Star Investor Andreas Halvorsen holds 1.02M shares of this stock.

Analyst Rating

Based on 34 analysts
Buy
Current Rating
96.026
Target Price
+9.92%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

FAQs

How does TradingKey generate the Stock Score of Edwards Lifesciences Corp?

The TradingKey Stock Score provides a comprehensive assessment of Edwards Lifesciences Corp based on 34 indicators derived from over 100 underlying data points.
These indicators are categorised into six key dimensions: financial health, company profile, earnings forecasts, price momentum, institutional confidence, and risk assessment, collectively providing investors with a thorough analysis of Edwards Lifesciences Corp’s performance and outlook.

How do we generate the financial health score of Edwards Lifesciences Corp?

To generate the financial health score of Edwards Lifesciences Corp, we analyse various key financial indicators across several core dimensions, including financial fundamentals, earnings quality, operational efficiency, growth potential, and shareholder returns.
By integrating these comprehensive data, the financial health score not only reflects Edwards Lifesciences Corp's overall stability, operational efficiency, and growth potential but also captures the investment returns delivered to shareholders. This score aims to support rational decision-making for investors and other stakeholders. A higher score indicates a better financial health of Edwards Lifesciences Corp.

How do we generate the company valuation score of Edwards Lifesciences Corp?

To generate the company valuation score of Edwards Lifesciences Corp, we use several key financial ratios, including P/E, P/B, P/S, and P/CF. These metrics compare Edwards Lifesciences Corp’s market value to its earnings, assets, sales, and cash flow, serving as core indicators for assessing company value.
By analysing these ratios in an all-round manner, the valuation score reflects not only the market’s current perception of Edwards Lifesciences Corp’s value but also its future profitability and growth potential, thereby supporting more informed investment decisions. A higher score indicates a fairer valuation of Edwards Lifesciences Corp.

How do we generate the earnings forecast score of Edwards Lifesciences Corp?

To calculate the earnings forecast score of Edwards Lifesciences Corp, we consider various key indicators such as analyst ratings, financial forecasts, support and resistance levels, and peer comparisons:
Current ratings and price targets directly reflect analysts’ expectations, while the upside space indicates their views on the stock’s growth potential.
Financial metrics like earnings per share (EPS), revenue, net income, and earnings before interest and taxes (EBIT) are core measures for assessing profitability.
By analysing the high, median, and low ranges of the target price, we can identify price trends and determine key support and resistance levels.
Comparing these indicators against peers provides context for the stock’s performance and helps anchor more realistic expectations.
These factors together form a comprehensive earnings forecast score that accurately reflects the stock’s expected financial performance and growth potential. A higher score suggests that analysts have a more optimistic outlook on Edwards Lifesciences Corp’s future.

How do we generate the price momentum score of Edwards Lifesciences Corp?

When generating the price momentum score for Edwards Lifesciences Corp, we examine momentum indicators including support and resistance levels as well as volume metrics.
Support levels represent price points where buying interest is strong enough to prevent further declines, while resistance levels indicate prices where selling pressure may hinder upward movement. By analysing typical price volume alongside total volume, we assess overall market activity and liquidity. These indicators help identify price trends and potential shifts, enabling more accurate predictions of future earnings.
This comprehensive approach can reflect market sentiment and enable rational forecasts of Edwards Lifesciences Corp’s prices. A higher score indicates a more stable short-term price trend for Edwards Lifesciences Corp.

How do we generate the institutional confidence score of Edwards Lifesciences Corp?

To generate the institutional confidence score of Edwards Lifesciences Corp, we analyse both the proportion of shares held by institutions and the number of shares they own. A higher institutional ownership percentage indicates strong confidence of professional investors, which is generally a positive signal about Edwards Lifesciences Corp’s potential. By examining the number of shares held, we gain deeper insight into institutions’ commitment and attitude toward the stock, as institutional investors typically conduct thorough analysis before making investment decisions. Understanding institutional confidence helps us refine earnings forecasts and provides a more reliable perspective on the company’s future performance and market stability. A higher score indicates greater institutional endorsement of Edwards Lifesciences Corp.

How do we generate the risk management score of Edwards Lifesciences Corp?

To assess the risk management score of Edwards Lifesciences Corp, we examine multiple key indicators related to returns, risk, volatility, and liquidity.
The highest and lowest daily returns reflect the potential size of gains and losses, while the Sharpe ratio measures risk-adjusted return performance. On the risk side, we analyse maximum drawdown and the return-to-drawdown ratio to identify extreme loss scenarios. Skewness helps assess the distribution of returns and whether performance may be biased. Volatility indicators—such as realised volatility and standardised true range—reveal price fluctuations. Downside risk-adjusted returns provide insight into potential losses and gains. Lastly, liquidity metrics like average turnover rate and turnover deviation indicate how actively the stock is traded.
These indicators together provide a multi-dimensional understanding of Edwards Lifesciences Corp’s risk-return profile, serving as core factors of the risk management score. A higher score indicates lower risk on the side of Edwards Lifesciences Corp.
KeyAI